Tango Therapeutics (NASDAQ:TNGX) Issues Quarterly Earnings Results

Tango Therapeutics (NASDAQ:TNGX) posted its quarterly earnings results on Monday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04), FiscalAI reports.

Tango Therapeutics Trading Up 6.9%

NASDAQ:TNGX opened at $24.30 on Wednesday. The firm has a market capitalization of $4.10 billion, a PE ratio of -17.74 and a beta of 1.26. Tango Therapeutics has a 1 year low of $7.49 and a 1 year high of $34.39. The firm’s fifty day simple moving average is $23.35 and its 200 day simple moving average is $22.59.

Analysts Set New Price Targets

Several research firms have recently weighed in on TNGX. William Blair assumed coverage on Tango Therapeutics in a research note on Friday, October 16th. They set an “outperform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Tango Therapeutics in a report on Wednesday, November 4th. HC Wainwright cut their target price on Tango Therapeutics from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Tuesday. Stifel Nicolaus set a $55.00 target price on Tango Therapeutics in a report on Friday, October 23rd. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $65.00 price target on shares of Tango Therapeutics in a research report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.54.

Insider Activity

In other news, insider Adam Crystal sold 27,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total transaction of $660,690.00. Following the completion of the transaction, the insider directly owned 115,743 shares in the company, valued at $2,832,231.21. The trade was a 18.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jessica Newcomb sold 8,200 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total transaction of $198,604.00. Following the transaction, the insider owned 59,121 shares of the company’s stock, valued at approximately $1,431,910.62. The trade was a 12.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 47,231 shares of company stock valued at $1,129,029 in the last three months. 6.50% of the stock is owned by insiders.

Trending Headlines about Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: JPMorgan raised its price target to $47 from $46 and reiterated an “overweight” rating, signaling substantial potential upside in the firm’s view. JPMorgan Chase & Co. Issues Positive Forecast for Tango Therapeutics Stock Price
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a 0.0-day days-to-cover ratio. The report’s claim of a significant increase in short interest appears inconsistent with those figures.
• Negative Sentiment: Wedbush cut its target to $40 from $45, and HC Wainwright lowered its target to $67 from $68. Both firms maintained bullish ratings—“outperform” and “buy,” respectively—but the target reductions temper the positive analyst outlook. Wedbush recommendations HC Wainwright recommendations
• Negative Sentiment: In its third-quarter results, Tango reported a loss of $0.39 per share, missing the consensus estimate of a $0.35 loss. The larger-than-expected loss may weigh on sentiment. Tango Therapeutics reports third-quarter 2026 results

About Tango Therapeutics

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.